Samsung Biologics launches all‑cash tender offer for PolyPeptide Group AG
Samsung Biologics Co. Ltd. (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO) specializing in biopharmaceutical products, has announced an all‑cash public tender offer to acquire 100 % of the fully diluted share capital of PolyPeptide Group AG (SIX: PPGN). The offer values PolyPeptide at CHF 44.31 per share, translating into an equity value of roughly CHF 1.46 billion.
Transaction structure and support
Under the transaction agreement, Samsung Biologics will purchase each share of PolyPeptide for CHF 44.31 in cash. The offer is backed by a unanimous recommendation from PolyPeptide’s board (through independent, non‑conflicted directors) and an irrevocable tender undertaking from the company’s largest shareholder, who holds 55.65 % of outstanding shares (excluding treasury shares). This strong endorsement signals confidence in the strategic fit between the two companies.
Strategic rationale
PolyPeptide is a specialist CDMO that focuses on the manufacture of peptide‑based active pharmaceutical ingredients (APIs). By integrating PolyPeptide’s expertise and its multi‑site manufacturing network across the United States, Europe, and India, Samsung Biologics aims to accelerate its multi‑modality strategy and broaden its global footprint. The acquisition is expected to enhance Samsung Biologics’ capacity to produce a wider range of biologics, including complex peptide therapeutics, and to offer clients a more diversified suite of contract services.
Impact on Samsung Biologics’ portfolio
Samsung Biologics already delivers a comprehensive portfolio of services—upstream and downstream manufacturing, analytical technology, cell culture and purification, aseptic fill‑and‑finish, lyophilization, and quality control—for biopharmaceutical companies worldwide. Adding PolyPeptide’s peptide specialization is anticipated to complement the company’s existing strengths in mammalian cell culture and biopharmaceutical manufacturing, thereby expanding its service offering and strengthening its competitive position in the global CDMO market.
Financial snapshot
As of the close on 15 July 2026, Samsung Biologics traded at KRW 1,396,000 per share, with a 52‑week high of KRW 1,987,000 and a 52‑week low of KRW 1,020,000. The company’s market capitalization stands at KRW 64.62 trillion, and its price‑to‑earnings ratio is 52.54. The tender offer represents a significant capital outlay but is aligned with the company’s long‑term growth objectives across portfolio breadth, geographic reach, and manufacturing capacity.
Conclusion
Samsung Biologics’ all‑cash tender offer for PolyPeptide Group AG marks a decisive step toward consolidating its position as a leading global CDMO. By leveraging PolyPeptide’s peptide expertise and expanding its manufacturing network, the company aims to deliver enhanced value to its clients and drive sustainable growth across the biopharmaceutical industry.
